By Taylor Mixides – Drug Target Review
Autologous haematopoietic stem cell transplantation (aHSCT), a medical procedure typically employed in the treatment of blood cancers, holds promise as a potential therapy for individuals with relapsing-remitting multiple sclerosis (RRMS).
Published in the Journal of Neurology Neurosurgery & Psychiatry. This innovative approach involves the extraction of a patient’s own stem cells from either their bone marrow or blood, followed by a course of chemotherapy and antibody treatment. While aHSCT has shown potential benefits for RRMS patients, it has not yet garnered widespread inclusion in national clinical guidelines.
